MedPath

Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy

Completed
Conditions
Bronchial Asthma
Registration Number
NCT01711840
Lead Sponsor
AstraZeneca
Brief Summary

The purpose of the investigation is to confirm the safety of patients receiving Symbicort Turbuhaler as maintenance and reliever therapy ( Symbicort SMART) under the post-marketing actual use.

Detailed Description

Symbicort Turbuhaler 30/60 Clinical Experience Investigation for treatment with Symbicort as maintenance therapy and as needed in response to symptoms

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2409
Inclusion Criteria
  • Patients receiving Symbicort Turbuhaler as maintenance and reliever therapy for the first time due to 'bronchial asthma ',and possibly requiring as-needed inhalations during the observation period
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Adverse event incidence12 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Research Site

🇯🇵

Yamanashi, D589ll00001, Japan

© Copyright 2025. All Rights Reserved by MedPath